News - Boehringer Ingelheim, Pharmaceutical

Filter

Popular Filters

1 to 25 of 169 results

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

02-07-2014

German family-owned pharma major Boehringer Ingelheim says it has submitted Marketing Authorization Applications…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and Pulmonarytiotropium + olodaterol Respimat

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

FDA Breakthrough status for Boehringer’s investigational Pradaxa antidote

26-06-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to idarucizumab, an…

Boehringer IngelheimCardio-vascularidarucizumabPharmaceuticalPradaxaRegulationResearchUSA

Boehringer Ingelheim pulls out of hepatitis C drug development

Boehringer Ingelheim pulls out of hepatitis C drug development

23-06-2014

German family-owned pharma major Boehringer Ingelheim revealed that, following a re-evaluation of its…

Anti-viralsBoehringer IngelheimfaldaprevirPharmaceuticalRegulationResearch

Boehringer and Lilly re-file empagliflozin NDA with FDA

Boehringer and Lilly re-file empagliflozin NDA with FDA

19-06-2014

The US subsidiary of German family-owned drugmaker Boehringer Ingelheim and pharma major Eli Lilly have…

Boehringer IngelheimDiabetesEli LillyempagliflozinPharmaceuticalRegulationUSA

ADA 2014: Investigational new insulin glargine from Lilly and Boehringer comparable to Lantus

ADA 2014: Investigational new insulin glargine from Lilly and Boehringer comparable to Lantus

15-06-2014

For the first time, US pharma major Eli Lilly and family-owned German major Boehringer Ingelheim presented…

BiosimilarsBoehringer IngelheimDiabetesEli LillyInsulin Glargine [rDNA origin] InjectionLantusLY2963016PharmaceuticalResearchSanofi

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

Boehringer’s Pradaxa gains added indication in Europe

Boehringer’s Pradaxa gains added indication in Europe

06-06-2014

German family-owned pharma major Boehringer Ingelheim said today that its blood thinner Pradaxa (dabigatran…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaRegulation

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

05-06-2014

German family-owned pharma major Boehringer Ingelheim said this morning that the European Medicines Agency…

Boehringer IngelheimEuropenintedanibPharmaceuticalRegulationRespiratory and Pulmonary

Boehringer resolves FDA manufacturing facility concerns

Boehringer resolves FDA manufacturing facility concerns

03-06-2014

German family-owned pharma major Boehringer Ingelheim said today that it has been notified by a letter…

Boehringer IngelheimFood and Drug AdministrationGermanyPharmaceuticalPharmaceutical sciencesProductionRegulationResearchUSA

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

02-06-2014

After facing more than 2,000 law suits in the USA, claiming Pradaxa (dabigatran) caused severe or fatal…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceutical

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

Boehringer and Lilly’s diabetes drug Jardiance gains EU approval

23-05-2014

German family-owned pharma major Boehringer Ingelheim and US partner Eli Lilly have received Marketing…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

First Ph III data on Boehringer’s fixed-dose combo tiotropium plus olodaterol in COPD

22-05-2014

German family-owned drug major Boehringer Ingelheim has presented positive results of the VIVACITO (NCTO1559116)…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and Pulmonarytiotropium

FDA finds favorable risk:benefit balance for Boehringer’s Pradaxa

18-05-2014

As part of its ongoing review, the US Food and Drug Administration last week released latest findings…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaRegulationUSA

Boehringer Ingelheim to make detailed clinical trial data more widely available

Boehringer Ingelheim to make detailed clinical trial data more widely available

12-05-2014

In order to add to scientific and medical progress, family-owned German pharma major Boehringer Ingelheim…

Boehringer IngelheimPharmaceuticalResearch

Greater brand-drug adoption fuels Asia-Pacific breast cancer market

09-05-2014

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics…

afatinibAsia-PacificBoehringer IngelheimEisaiHalavenKadcylaMarkets & MarketingneratinibOncologypalbociclibPerjetaPfizerPharmaceuticalResearchRoche

Hydra Biosciences and Boehringer Ingelheim collaborate on CNS research

25-04-2014

Privately-held US biopharma firm Hydra Biosciences and family-owned German drug major Boehringer Ingelheim…

Boehringer IngelheimHydra BiosciencesNeurologicalPharmaceuticalResearch

US oncologists prescribing of Boehringer's Gilotrif for NSCLC

25-04-2014

Just six months post-launch in the USA, 49% of surveyed US medical oncologists have prescribed German…

Boehringer IngelheimGilotrifMarkets & MarketingOncologyPharmaceuticalUSA

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Boehringer Ingelheim’s volasertib granted orphan drug designation for AML

Boehringer Ingelheim’s volasertib granted orphan drug designation for AML

17-04-2014

The US Food and Drug Administration and the European Commission have granted German family-owned drug…

Boehringer IngelheimEuropeGermanyHealth Medical PharmaMajorMedicineOncologyPharmaceuticalPharmacologyRegulationUS Food and Drug AdministrationUSAvolasertib

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

Boehringer Ingelheim posts 2013 financials with currency adjusted sales up 1.4%

15-04-2014

German family-owned drug major Boehringer Ingelheim today posted financial results for 2013, noting that,…

Boehringer IngelheimFinancialPharmaceutical

NDA filing for empagliflozin and linagliptin combo accepted by FDA

NDA filing for empagliflozin and linagliptin combo accepted by FDA

14-04-2014

The US Food and Drug Administration has accepted the filing of the New Drug Application for the investigational…

Boehringer IngelheimDiabetesEli LillyempagliflozinJardiancelinagliptinNorth AmericaPharmaceuticalRegulationTradjentaUSA

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

07-04-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationUSA

EMA/CHMP recommends empagliflozin for approval for type 2 diabetes

23-03-2014

German family-owned drug major Boehringer Ingelheim and partner Eli Lilly of the USA have announce a…

Boehringer IngelheimDiabetesEli LillyempagliflozinEuropeJardiancePharmaceuticalRegulation

1 to 25 of 169 results

Back to top